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Chronic infection with hepatitis B virus (HBV) continues to be a
major health problem affecting about 400 million people
worldwide. The narrow species tropism of HBV has hindered
progresses in HBV research and development of more efﬁcient
treatments. Due to strong restraints encountered using chimpan-
zees and animal models based on HBV-related viruses, recent
developments focused on using the natural target of HBV infec-
tion: the human hepatocyte. However, in vitro susceptibility of
human hepatocytes to HBV is limited and cultured cells may
respond differently to the infection and other stimuli than hepa-
tocytes in the liver. Attempts to create mice harboring human
chimeric livers led to the establishment of two major models:
the urokinase-type plasminogen activator (uPA) transgenic mice
[8] and the knockout fumarylacetoacetate hydrolase (Fah) mice
[1]. Common features of these systems are: (i) a transgene-
induced hepatocyte damage creating space and regenerative
stimulus for the transplanted cells to repopulate the host livers,
and (ii) the absence of adaptive immune responses permitting
xenogenic transplantation. Both models are amenable of infec-
tion with HBV [2,3]. Here we present recent advances and appli-
cations of the uPA model, the most used and best characterized
chimeric model currently available for HBV infection studies
and preclinical drug evaluation.Generation of human chimeric uPA/SCID mice
(1) Expression of a liver-toxic uPA transgene, driven by an albu-
min promoter, induces subacute liver failure in newborn animals,
promoting strong growth advantage for transplanted hepatocytes
[8]. Although transgene deletion takes place in individual mouse
hepatocytes, inactivation of both transgene alleles in the same
cell is a rare event. Consequently, mortality of homozygous uPA
mice is high, unless mouse livers are reconstituted with healthyJournal of Hepatology 20
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strains lacking functional B- and T-cells, like Severe Combined
Immune Deﬁcient (SCID) mice, permits human hepatocytes
engraftment [3,7].
(2) One million human hepatocytes isolated from surgical
liver remnants or explanted livers are injected intra-splenically
into 2- to 3-week-old homozygous uPA/SCID mice. The use of
high-viable cryopreserved-thawed hepatocytes [5,10] permits
to generate a large number of mice displaying high levels of
human chimerism on demand, thus overcoming previous limita-
tions due to the narrow time frame available for transplantation.
(3) One week post-transplantation small clusters of human
hepatocytes start to proliferate within the pale mouse liver, as
shown by human speciﬁc cytokeratin-18 and Ki-67 double stain-
ing, and expand to constitute larger regenerative nodules which
eventually merge together, replacing the diseased liver paren-
chyma in variable proportions. Mouse liver reconstitution takes
8–10 weeks and can be monitored by measuring human albumin
concentrations in mouse serum [5].Current and potential applications of the model for HBV
studies
(4) While mouse hepatocytes do not support HBV infection,
human-chimeric mice can be efﬁciently infected by injecting
infectious serum derived from either patients or chimeric mice.
Furthermore, genetically engineered viruses created in cell cul-
ture can be used to investigate phenotype and in vivo ﬁtness of
distinct HBV genotypes and variants [9].
(5) HBV spreading phase: Establishment of HBV infection
requires the formation of the cccDNA minichromosome, the
HBV transcriptional template. This step is achieved, initially, in
very few human hepatocytes. Three weeks post-infection only
sporadic cells stain HBcAg-positive, while at week 6 the majority
of human hepatocytes are infected. Thus, several weeks are
needed for HBV to spread among human hepatocytes, as docu-
mented by the gradual increase of HBcAg-positive human hepa-
tocytes. Within this time frame the system offers unique
possibilities to study the early phase of infection, as well as for
preclinical evaluation of agents interfering with viral entry, such
as HBV-derived peptides [7] and neutralizing antibodies, or with
cccDNA formation.
(6) HBV chronic phase: When HBV spreading is accomplished,
nearly all human hepatocytes stain HBcAg-positive and viremia12 vol. 56 j 493–495
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Fig. 1. Current and potential applications of human liver chimeric uPA/SCID mice for HBV infection studies and preclinical antiviral drug evaluation.
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copies/ml, which fairly correlates with the levels of human chi-
merism. Mice with 10–70% repopulation levels display stable494 Journal of Hepatology 201HBV titres (up to 5x108) and thus are ideal to perform long-term
antiviral testing, while higher human repopulation levels lead to
renal insufﬁciency and lower mouse survival rates.2 vol. 56 j 493–495
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(7) Within the mouse liver human hepatocytes maintain a
functional innate immune system and respond to stimuli induced
by exogenously applied human IFN-a. The lack of an adaptive
immune system and the undetectable responsiveness of mouse
liver cells to human IFN-a make the model ideal to exploit the
capacities of HBV to interfere with pathways of the innate antivi-
ral response in human hepatocytes [5].
(8) Chimeric mice can be super-infected or simultaneously
infected with different human hepatotropic viruses to investigate
mechanisms of virus interference and response to antiviral treat-
ment in the setting of co-infection [4].
(9) Serial passage of human hepatocytes in uPA/SCID mice
may enable investigation of the impact of hepatocyte prolifera-
tion on cccDNA stability and activity in vivo [6].
The feasibility of generating uPA/SCID mice containing both
human liver and immune cells awaits investigation.Conﬂict of interest
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